Related Experiment Video

Updated: Jul 10, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication

Min-Hyuk Yoo1, Xue-Ming Xu, Bradley A Carlson

  • 1Molecular Biology of Selenium Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

Plos One
|November 1, 2007
PubMed

Insights

Thioredoxin reductase 1 (TR1) is overexpressed in cancer cells and drives malignant growth. Reducing TR1 levels reverses cancer cell characteristics, highlighting its potential as a cancer therapy target.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Thioredoxin reductase 1 (TR1) is a key antioxidant selenoprotein regulating cell redox balance.
  • TR1 is paradoxically overexpressed in cancer cells despite its antioxidant role, and is a target for cancer drugs.
  • Previous studies suggest TR1 deficiency is antitumorigenic, but its molecular role in cancer is unclear.

Purpose of the Study:

  • To investigate the molecular basis of TR1's role in cancer development.
  • To determine if TR1 functions as a pro-cancer or anti-cancer protein.
  • To evaluate TR1 as a potential therapeutic target in cancer.

Main Methods:

  • TR1 knockdown in a k-ras-driven mouse cancer cell line.
  • Morphological analysis of TR1-deficient cancer cells.
  • Assessment of cell growth, cell cycle progression (S phase), and DNA polymerase alpha expression under serum-deficient conditions.

Main Results:

  • TR1 is uniquely overexpressed in cancer cells compared to other selenoproteins.
  • TR1 knockdown induced morphological reversion to parental cell characteristics without affecting growth under normal conditions.
  • TR1-deficient cancer cells lost growth self-sufficiency, showed defective S phase progression, and reduced DNA polymerase alpha expression in serum-deficient medium.

Conclusions:

  • TR1 is critical for the self-sufficiency of growth signals in malignant cells.
  • TR1 primarily acts as a pro-cancer protein, supporting cancer cell survival and proliferation.
  • TR1 is a validated primary target for cancer therapy.

More Related Videos

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...